Boetto et al. (2017) showed that SMO-mutated meningiomas had a higher recurrence rate with respect to AKT1 mutated-meningiomas and that, overall, SMO-mutated meningiomas had a poor prognosis as compared to AKT1-mutated ones [327]. The gene discussed is SMO; the disease is meningioma.